Abstract
We have not added the abstract for this paper yet. The publisher's page has the full record.
P-015: A responder analysis of MPC-7869 (tarenflurbil), a selective Abeta42-lowering agent, in mild Alzheimer's disease (AD): Analysis from a phase 2 study of up to 24 months of treatment
Alzheimer's & Dementia · Vol. 3 Published January 1, 2007
More on these topics
Browse all publications →-
2026 · Alzheimers Dement
Biomarkers in patients with clinical signs of mild cognitive impairment or mild Alzheimer's disease but without amyloid deposits on positron emission tomography: Results from Bio-Hermes Study participants
-
2026 · The Journal of Prevention of Alzheimer's Disease
Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer’s disease
-
2025 · Journal of Alzheimer’s Disease
Efficacy of AD04, an aluminum-based vaccine adjuvant, in patients with early Alzheimer's disease: Post hoc analysis of AFF006 (NCT01117818), a proof-of-concept, phase 2 randomized controlled trial
-
2024 · Alzheimers Dement (N Y)
Biological effects of sodium phenylbutyrate and taurursodiol in Alzheimer's disease